A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

  • STATUS
    Not Recruiting
  • End date
    Oct 22, 2022
  • participants needed
    189
  • sponsor
    AbbVie
Updated on 23 May 2022
pulmonary function test
fibrosis

Summary

This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.

Details
Condition Cystic Fibrosis
Treatment ABBV-3067, Placebo ABBV-3067, ABBV-2222, Placebo ABBV-2222
Clinical Study IdentifierNCT03969888
SponsorAbbVie
Last Modified on23 May 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note